Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing/advanced practice provider perspectives.

IF 2.3 4区 医学 Q1 NURSING Seminars in Oncology Nursing Pub Date : 2024-11-22 DOI:10.1016/j.soncn.2024.151758
Nicole McEntee, Jacqueline Manago, ChiaChun Lu, Lucy Holmes
{"title":"Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing/advanced practice provider perspectives.","authors":"Nicole McEntee, Jacqueline Manago, ChiaChun Lu, Lucy Holmes","doi":"10.1016/j.soncn.2024.151758","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Lisocabtagene maraleucel (liso-cel; Breyanzi), an autologous chimeric antigen receptor T-cell therapy, has demonstrated efficacy and safety in relapsed/refractory large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. Outpatient monitoring after liso-cel administration has shown lower health care resource utilization and cost and high patient satisfaction. However, outpatient monitoring programs require well-designed processes with collaborations from multiple stakeholders across several facilities. The study objective is to provide learnings and key considerations from nurses and advanced practice providers (APP) with experience setting up and managing liso-cel outpatient monitoring programs.</p><p><strong>Data source: </strong>Author experience gathered from 3 institutions at 2 workshops.</p><p><strong>Results: </strong>In the reviewed programs, patients are discharged on the same day after liso-cel infusion and observation. They are required to remain within a short distance of the facility for ≥4 weeks with admission to treatment facilities upon experiencing adverse events (AE). Nurses/APPs report several key features of successful programs: flexibility to carry out essential roles/functions based on institution's resources and staff structure, a phased or hybrid (hospital/clinic) approach to program launch, a core team to run and guide the program, robust training for staff, options to tailor AE monitoring based on institution guidelines, and coordinated transitions between multiple stakeholders and facilities.</p><p><strong>Conclusions: </strong>Nurses/APPs are critical contributors to liso-cel outpatient monitoring programs. Success in providing appropriate, complex individualized care in these programs can be achieved by using a multistakeholder approach with appropriate staff and patient/caregiver training and careful coordination across multiple functions and facilities.</p><p><strong>Implications for nursing practice: </strong>The learnings and resources presented may provide insight to considerations around the development of a cell therapy outpatient monitoring program. However, the information provided here should be taken together with other relevant resources and guidelines and should be adapted to align with the institution's own guidelines.</p>","PeriodicalId":54253,"journal":{"name":"Seminars in Oncology Nursing","volume":" ","pages":"151758"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Oncology Nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.soncn.2024.151758","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Lisocabtagene maraleucel (liso-cel; Breyanzi), an autologous chimeric antigen receptor T-cell therapy, has demonstrated efficacy and safety in relapsed/refractory large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. Outpatient monitoring after liso-cel administration has shown lower health care resource utilization and cost and high patient satisfaction. However, outpatient monitoring programs require well-designed processes with collaborations from multiple stakeholders across several facilities. The study objective is to provide learnings and key considerations from nurses and advanced practice providers (APP) with experience setting up and managing liso-cel outpatient monitoring programs.

Data source: Author experience gathered from 3 institutions at 2 workshops.

Results: In the reviewed programs, patients are discharged on the same day after liso-cel infusion and observation. They are required to remain within a short distance of the facility for ≥4 weeks with admission to treatment facilities upon experiencing adverse events (AE). Nurses/APPs report several key features of successful programs: flexibility to carry out essential roles/functions based on institution's resources and staff structure, a phased or hybrid (hospital/clinic) approach to program launch, a core team to run and guide the program, robust training for staff, options to tailor AE monitoring based on institution guidelines, and coordinated transitions between multiple stakeholders and facilities.

Conclusions: Nurses/APPs are critical contributors to liso-cel outpatient monitoring programs. Success in providing appropriate, complex individualized care in these programs can be achieved by using a multistakeholder approach with appropriate staff and patient/caregiver training and careful coordination across multiple functions and facilities.

Implications for nursing practice: The learnings and resources presented may provide insight to considerations around the development of a cell therapy outpatient monitoring program. However, the information provided here should be taken together with other relevant resources and guidelines and should be adapted to align with the institution's own guidelines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
lisocabtagene maraleucel嵌合抗原受体T细胞疗法门诊监测计划的实施:多中心护理/高级医疗服务提供者的观点。
研究目的Lisocabtagene maraleucel(liso-cel;Breyanzi)是一种自体嵌合抗原受体T细胞疗法,对复发/难治性大B细胞淋巴瘤、慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、滤泡淋巴瘤和套细胞淋巴瘤具有疗效和安全性。使用 liso-cel 后的门诊监测显示,医疗资源使用率和成本较低,患者满意度较高。然而,门诊监测计划需要多个机构的多方利益相关者通力合作,精心设计流程。本研究旨在提供护士和高级医疗服务提供者(APP)在建立和管理利索塞尔门诊监测项目方面的经验和主要注意事项:数据来源:作者在 2 次研讨会上从 3 家机构收集的经验:在所审查的项目中,患者在输注和观察利索凝胶后当天即可出院。他们需要在医疗机构附近逗留≥4周的时间,一旦出现不良反应(AE),则需转入治疗机构。护士/APPs 报告了成功项目的几个关键特征:根据机构的资源和人员结构灵活履行基本角色/职能、分阶段或混合(医院/诊所)方式启动项目、核心团队运行和指导项目、对员工进行强有力的培训、根据机构指南定制 AE 监测选项,以及在多个利益相关者和机构之间协调过渡:结论:护士/APP 是 liso-cel 门诊监测项目的重要贡献者。通过采用多方参与的方法,对员工和患者/护理人员进行适当的培训,并在多个职能部门和机构之间进行细致的协调,可以成功地在这些项目中提供适当、复杂的个性化护理:本文介绍的知识和资源可为制定细胞治疗门诊病人监测计划提供参考。然而,此处提供的信息应与其他相关资源和指南一并考虑,并应根据机构自身的指南进行调整。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in Oncology Nursing
Seminars in Oncology Nursing Nursing-Oncology (nursing)
CiteScore
3.40
自引率
0.00%
发文量
68
审稿时长
45 days
期刊介绍: Seminars in Oncology Nursing is a unique international journal published six times a year. Each issue offers a multi-faceted overview of a single cancer topic from a selection of expert review articles and disseminates oncology nursing research relevant to patient care, nursing education, management, and policy development.
期刊最新文献
Table of Contents Masthead Nonpharmacological Interventions for the Fatigue–Pain–Sleep Disturbance Symptom Cluster in Lung Cancer Patients: Best Evidence Summary Development of a Scale to Assess Cancer Attitude in the Community The Effect of Virtual Reality Distraction and Fatigue Training on Anxiety and Fatigue Levels in Children with Cancer: A Randomized Controlled Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1